Version 1
: Received: 7 April 2024 / Approved: 8 April 2024 / Online: 9 April 2024 (03:28:40 CEST)
How to cite:
Mishra, K.; Khatib, N.; Barasch, D.; Garti, S.; Garti, N.; Kakhlon, O. A New Tailored Nano-Droplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant Efficacy. Preprints2024, 2024040556. https://doi.org/10.20944/preprints202404.0556.v1
Mishra, K.; Khatib, N.; Barasch, D.; Garti, S.; Garti, N.; Kakhlon, O. A New Tailored Nano-Droplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant Efficacy. Preprints 2024, 2024040556. https://doi.org/10.20944/preprints202404.0556.v1
Mishra, K.; Khatib, N.; Barasch, D.; Garti, S.; Garti, N.; Kakhlon, O. A New Tailored Nano-Droplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant Efficacy. Preprints2024, 2024040556. https://doi.org/10.20944/preprints202404.0556.v1
APA Style
Mishra, K., Khatib, N., Barasch, D., Garti, S., Garti, N., & Kakhlon, O. (2024). A New Tailored Nano-Droplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant Efficacy. Preprints. https://doi.org/10.20944/preprints202404.0556.v1
Chicago/Turabian Style
Mishra, K., Nissim Garti and Or Kakhlon. 2024 "A New Tailored Nano-Droplet Carrier of Astaxanthin Can Improve Its Pharmacokinetic Profile and Antioxidant Efficacy" Preprints. https://doi.org/10.20944/preprints202404.0556.v1
Abstract
Astaxanthin (ATX) is a carotenoid nutraceutical with a poor bioavailability due to its high lipophilicity. We tested a new tailored nano-droplet capable of solubilizing ATX in an oil-in-water micro-environment (LDS-ATX, manufactured by Lyotropic Delivery Systems (LDS)), for its capacity to improve ATX pharmacokinetic profile and anti-oxidant efficacy. We used liquid chromatography tandem mass spectrometry (LC-MS/MS) to compare the pharmacokinetic profile of ATX and LDS-ATX and protein carbonylation and lipid peroxidation assays to compare their basal and lipopolysaccharide (LPS)-induced oxidative damage. Our results show that only LPS-induced oxidative damage was corrected by ATX and LDS-ATX. While in the liver and muscle LDS-ATX was more efficacious than ATX in attenuating oxidative damage to both proteins and lipids, only oxidative damage to lipids was preferably corrected by LDS-ATX in the brain. These results strongly suggest improvement of ATX bioavailability and efficacy by the LDS-ATX nano-formulation.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
